Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure
Ischemic heart disease is the main cause of morbidity and mortality worldwide and is becoming more widespread with population aging. Cardioprotection is a dynamic process characterized by mechanisms related to myocardial damage and activation of protective factors. Targeting these processes could be...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2019.00927/full |
| _version_ | 1828372905630629888 |
|---|---|
| author | Francesca Mastorci Laura Sabatino Cristina Vassalle Alessandro Pingitore |
| author_facet | Francesca Mastorci Laura Sabatino Cristina Vassalle Alessandro Pingitore |
| author_sort | Francesca Mastorci |
| collection | DOAJ |
| description | Ischemic heart disease is the main cause of morbidity and mortality worldwide and is becoming more widespread with population aging. Cardioprotection is a dynamic process characterized by mechanisms related to myocardial damage and activation of protective factors. Targeting these processes could be attractive as a new therapeutic strategy in the evolution of post-ischemic heart failure (HF). In this context, the role of thyroid hormone (TH)-mediated cardioprotection is supported by a number of findings regarding the modulation of neuroendocrine systems, inflammatory and oxidative stress status, pro-survival intracellular pathways, and epigenetic factors, its effects on cardiac angiogenesis, structure, and function and on the preservation of mitochondrial function and morphology, and its beneficial effects on cell growth and redifferentiation. Moreover, the numerous effects of TH on the heart involve genomic mechanisms, which include cardiac differentiation during the perinatal period and non-genomic action, directed toward the maintenance of cardiovascular homeostasis. This evidence suggests that there is an opportunity to treat HF patients with TH. This review is mainly focused on the clinical evidence of the role of the thyroid system in the complex setting of HF. |
| first_indexed | 2024-04-14T07:10:49Z |
| format | Article |
| id | doaj.art-cf55ba68603f449db7c5473b0b7f3472 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-14T07:10:49Z |
| publishDate | 2020-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-cf55ba68603f449db7c5473b0b7f34722022-12-22T02:06:27ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922020-01-011010.3389/fendo.2019.00927473127Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart FailureFrancesca Mastorci0Laura Sabatino1Cristina Vassalle2Alessandro Pingitore3Clinical Physiology Institute, CNR, Pisa, ItalyClinical Physiology Institute, CNR, Pisa, ItalyFondazione G. Monasterio, CNR-Regione Toscana, Pisa, ItalyClinical Physiology Institute, CNR, Pisa, ItalyIschemic heart disease is the main cause of morbidity and mortality worldwide and is becoming more widespread with population aging. Cardioprotection is a dynamic process characterized by mechanisms related to myocardial damage and activation of protective factors. Targeting these processes could be attractive as a new therapeutic strategy in the evolution of post-ischemic heart failure (HF). In this context, the role of thyroid hormone (TH)-mediated cardioprotection is supported by a number of findings regarding the modulation of neuroendocrine systems, inflammatory and oxidative stress status, pro-survival intracellular pathways, and epigenetic factors, its effects on cardiac angiogenesis, structure, and function and on the preservation of mitochondrial function and morphology, and its beneficial effects on cell growth and redifferentiation. Moreover, the numerous effects of TH on the heart involve genomic mechanisms, which include cardiac differentiation during the perinatal period and non-genomic action, directed toward the maintenance of cardiovascular homeostasis. This evidence suggests that there is an opportunity to treat HF patients with TH. This review is mainly focused on the clinical evidence of the role of the thyroid system in the complex setting of HF.https://www.frontiersin.org/article/10.3389/fendo.2019.00927/fullcardioprotectionheart failureepigeneticthyroid hormonessubclinical thyroid disorders |
| spellingShingle | Francesca Mastorci Laura Sabatino Cristina Vassalle Alessandro Pingitore Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure Frontiers in Endocrinology cardioprotection heart failure epigenetic thyroid hormones subclinical thyroid disorders |
| title | Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure |
| title_full | Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure |
| title_fullStr | Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure |
| title_full_unstemmed | Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure |
| title_short | Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure |
| title_sort | cardioprotection and thyroid hormones in the clinical setting of heart failure |
| topic | cardioprotection heart failure epigenetic thyroid hormones subclinical thyroid disorders |
| url | https://www.frontiersin.org/article/10.3389/fendo.2019.00927/full |
| work_keys_str_mv | AT francescamastorci cardioprotectionandthyroidhormonesintheclinicalsettingofheartfailure AT laurasabatino cardioprotectionandthyroidhormonesintheclinicalsettingofheartfailure AT cristinavassalle cardioprotectionandthyroidhormonesintheclinicalsettingofheartfailure AT alessandropingitore cardioprotectionandthyroidhormonesintheclinicalsettingofheartfailure |